RxDoctor Payments Data

Stephen Hauser

Internal Medicine · San Francisco, CANPI 1700996931

Payments from drug & device makers

$72,330in general payments, 2019–2025

Across 85 payments — averaging $850.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • F. Hoffmann-la Roche AG$43K
  • Novartis Pharma AG$11K
  • Genentech, Inc.$9K
  • Modernatx, Inc.$4K
  • Gilead$3K
  • BD$2K
  • plus $485 from 5 others
$134,895in research payments, 2019–2025

Across 102 payments — averaging $1322.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • F. Hoffmann-la Roche AG$126K
  • Novartis Pharma AG$6K
  • Novartis$2K

What the payments were for

  • Consulting fees$9,28913%
  • Speaking & faculty fees$33,17046%
  • Travel & lodging$29,02140%
  • Food & beverage$8511%

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$72,330 in reported general payments places this provider in the 95th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dalfampridine ErDalfampridine17$2,060

Paid to pharmacies, not to this prescriber.

Other internal medicine in San Francisco

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →